PTGX Q1 2021 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+69.7% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$24M-388.1% margin

Net Income

-$24M-387.8% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$298M

Total Liabilities

$39M

Stockholders' Equity

$259M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+69.7%
Gross Profit	$6M	$4M	+69.7%
Operating Income	-$24M	-$20M	-22.0%
Net Income	-$24M	-$20M	-19.5%

Revenue Segments

License And Collaborative Revenue

$96M99%

Financial Service Other

$600,0001%